-
Goserelin
- indication:Breast cancer; Prostate carcinoma; Endometriosis
- pharmacologypharmacology:
- mechanism: ZOLADEX is a synthetic decapeptide analogue of LHRH. ZOLADEX acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.
- toxicity: No experience of overdosage from clinical trials
- absorprion: Inactive orally, rapidly absorbed following subcutaneous administration
- halflife: 4-5 hours
- roouteelimination: Clearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.
- volumedistribution: * 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]
- clearance: * 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]